Eli Lilly and Company $LLY Position Decreased by Wright Investors Service Inc.

Wright Investors Service Inc. lowered its holdings in Eli Lilly and Company (NYSE:LLY) by 42.8% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 1,473 shares of the company’s stock after selling 1,102 shares during the quarter. Wright Investors Service Inc.’s holdings in Eli Lilly and Company were worth $1,124,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Brighton Jones LLC grew its holdings in shares of Eli Lilly and Company by 22.0% in the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after acquiring an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC boosted its position in shares of Eli Lilly and Company by 2.8% in the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after purchasing an additional 40 shares during the period. Seaside Wealth Management Inc. boosted its position in shares of Eli Lilly and Company by 3.9% in the 2nd quarter. Seaside Wealth Management Inc. now owns 691 shares of the company’s stock valued at $539,000 after purchasing an additional 26 shares during the period. Sapient Capital LLC increased its stake in Eli Lilly and Company by 0.8% in the 2nd quarter. Sapient Capital LLC now owns 1,218,487 shares of the company’s stock worth $949,847,000 after purchasing an additional 9,903 shares in the last quarter. Finally, Sunpointe LLC raised its holdings in Eli Lilly and Company by 14.9% during the 2nd quarter. Sunpointe LLC now owns 1,183 shares of the company’s stock worth $922,000 after buying an additional 153 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

LLY has been the subject of several recent analyst reports. Truist Financial raised their target price on shares of Eli Lilly and Company from $1,038.00 to $1,182.00 and gave the stock a “buy” rating in a report on Wednesday, November 19th. Wolfe Research upped their price target on shares of Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the company an “outperform” rating in a research report on Wednesday, December 3rd. HSBC reiterated a “hold” rating and set a $1,070.00 price objective on shares of Eli Lilly and Company in a research report on Wednesday, December 10th. Jefferies Financial Group increased their target price on Eli Lilly and Company from $976.00 to $1,300.00 and gave the company a “buy” rating in a report on Thursday, January 8th. Finally, JPMorgan Chase & Co. raised their target price on Eli Lilly and Company from $1,050.00 to $1,150.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 18th. Five analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $1,174.70.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: JPMorgan coverage highlights continued GLP‑1 sales strength and pipeline-driven momentum entering 2026, reinforcing expectations for revenue growth from obesity and next‑generation incretin candidates. JPM26: Eli Lilly enters 2026 with strong momentum given pipeline innovation
• Positive Sentiment: JPMorgan also highlights commercial and governmental access efforts for Lilly’s obesity drugs — implying management focus on scaling reimbursement and market penetration, which supports longer‑term sales trajectory. JPM26: Eli Lilly’s obesity drugs target commercial and governmental access
• Positive Sentiment: Analysts continue to back LLY: Jefferies reaffirmed a Buy with a $1,300 target and BMO kept a Buy — signals that sell‑side expectations remain bullish despite near‑term noise. Where is Eli Lilly and Company (LLY) Headed According to Analysts?
• Positive Sentiment: CEO David Ricks reiterated ambition and portfolio outlook (including obesity launches) in a recent interview, which supports confidence in execution and the company’s sizable market opportunity. Eli Lilly CEO David Ricks on $1T market value, obesity pill launch and drug pipeline outlook
• Neutral Sentiment: Lilly’s AI collaboration mentions (e.g., with NVIDIA) position the company on the technological edge of drug discovery — positive structurally but not an immediate revenue driver. JPM: NVIDIA Launches AI Collaborations with Eli Lilly, Thermo Fisher
• Negative Sentiment: FDA reportedly delayed its decision on Lilly’s oral obesity candidate orforglipron (a priority‑voucher recipient), creating uncertainty about near‑term market timing and catalyzing a negative trader reaction. FDA Delays Decision for Lilly’s Obesity Pill Orforglipron, Other Priority Voucher Awardees: Report
• Negative Sentiment: A compounding pharmacy has filed suit alleging coordinated conduct by Lilly and Novo Nordisk around GLP‑1 dominance; legal/legal‑risk headlines add regulatory and reputational uncertainty for the GLP‑1 franchise. Lilly, Novo sued over GLP‑1 drug dominance by compounding pharmacy

Eli Lilly and Company Stock Down 3.8%

LLY stock opened at $1,032.51 on Friday. The company has a 50 day moving average of $1,049.04 and a two-hundred day moving average of $868.38. The company has a market cap of $976.11 billion, a price-to-earnings ratio of 50.51, a PEG ratio of 0.78 and a beta of 0.35. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,133.95. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The business had revenue of $17.60 billion for the quarter, compared to analysts’ expectations of $16.09 billion. During the same period in the previous year, the company posted $1.18 EPS. Eli Lilly and Company’s revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, equities analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be paid a dividend of $1.73 per share. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date of this dividend is Friday, February 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. Eli Lilly and Company’s dividend payout ratio (DPR) is 29.35%.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.